DUESSELDORF, Germany & WASHINGTON & CARLSBAD, Calif.--(BUSINESS WIRE)--In the BIO-Europe opening plenary session (Monday, 11.30 – 12.30) the latest balance between Partnerships versus M&A is up for debate. With a slow IPO market and cash flush Big Pharma thirsty for pipeline fillers, M&A activity is vibrant. As such Biotechs can expect significant premiums on acquisition. On the one hand, the likes of Pfizer and Novartis are aggressively acquiring, and on the other Wyeth still prefers partnerships.
